Back to top
more

Heska Corporation (HSKA)

(Delayed Data from NSDQ)

$79.28 USD

79.28
71,295

+3.36 (4.43%)

Updated May 3, 2019 04:00 PM ET

After-Market: $79.10 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Roche (RHHBY) Hemophilia A Drug Positive in Phase III

Roche (RHHBY) announced that the phase III study, HAVEN 1, met its primary endpoint.

    Teva Settles Foreign Bribery Charges with U.S. Government

    Teva (TEVA) announced that it has completed negotiations with the U.S. government over violations of the Foreign Corrupt Practices Act.

      Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx

      Exelixis, Inc. (EXEL) announced that it has amended the exclusive collaboration and licensing agreement with its European partner Ipsen.

        Merrimack (MACK) Drops as Breast Cancer Drug Trial Stops

        Shares of Merrimack Pharmaceuticals, Inc. (MACK) tanked 18.4% after the company announced the discontinuation of a phase II trial on its breast cancer candidate, MM-302.

          Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo

          Bristol-Myers Squibb Company (BMY) announced a clinical trial collaboration with Calithera Biosciences, Inc. (CALA).

            Incyte/Merus Ink Collaboration for Bispecific Antibodies

            Incyte (INCY) entered into an agreement with Merus (MRUS) to discover and develop bispecific antibodies using the latter's proprietary Biclonics technology platform.

              Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU

              Pfizer Inc. (PFE) announced that the European Commission has approved an expanded indication for its meningococcal vaccine, Nimenrix.

                Juno Gets Breakthrough Therapy Status for Lymphoma Drug

                Juno Therapeutics, Inc. (JUNO) and partner Celgene Corporation (CELG), announced that the FDA has granted Breakthrough Therapy designation to their investigational candidate, JCAR017.

                  ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint

                  ACADIA Pharmaceuticals Inc. (ACAD) announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint.

                    J&J Files for FDA Approval of Simponi Aria Label Expansion

                    Johnson & Johnson's (JNJ), Janssen submitted two sBLAs in the U.S. seeking approval of Simponi Aria for the treatment of psoriatic arthritis and ankylosing spondylitis.

                      Biogen (BIIB) Board Okays Hemophilia Business Spin-off

                      Biogen (BIIB) announced that its board of directors has approved the spin-off of its hemophilia business into a new company Bioverativ Inc.

                        Allergan to Buy LifeCell to Boost Regenerative Medicine Suite

                        Allergan plc (AGN) announced that it has signed a definitive agreement to acquire LifeCell, the regenerative medicine unit of Texas-based privately held company Acelity for $2.9 billion in cash.

                          Sarepta's (SRPT) Application for DMD Drug Accepted in the EU

                          Sarepta Therapeutics, Inc. (SRPT) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization application (MAA) for Exondys 51.

                            Amgen Files for Approval of Osteoporosis Drug in Japan

                            Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that they have submitted an application seeking marketing approval for its investigational monoclonal antibody romosozumab to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

                              AbbVie (ABBV) Submits NDA for Next-Gen HCV Combo in US

                              AbbVie Inc. (ABBV) announced that it has submitted a New Drug Application (NDA) to the FDA for its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                                Ionis (IONS) Receives Milestone Payment from AstraZeneca

                                Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.

                                  Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis

                                  Incyte (INCY) and Eli Lilly (LLY) announced that the EMA's CHMP has issued a positive opinion for the approval of Olumiant (baricitinib).

                                    Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data

                                    Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.

                                      Intercept (ICPT) Ocaliva Gains Conditional Approval in EU

                                      Intercept (ICPT) Ocaliva, in combination with UDCA, was approved in the EU for the treatment of PBC.

                                        Kite Pharma Enters into Partnership with Vitruvian Networks

                                        Kite Pharma (KITE) entered into a strategic partnership with Vitruvian Networks to create a software solution to support commercial availability of T-cell therapies.

                                          Repros to Meet with the FDA for Phase III Proellex Program

                                          Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.

                                            Merck (MRK) Offers Update on Keytruda-Halaven Combination

                                            Merck (MRK) and Eisai (ESALY) announced new interim data from a phase Ib/II study on the Keytruda-Halaven combination for the treatment of metastatic TNBC.

                                              Novartis Offers Positive Data on Breast Cancer Drug LEE011

                                              Novartis (NVS) announced results from the phase III MONALEESA-2 study on LEE011 for the treatment of first-line HR+/HER2- advanced breast cancer.

                                                AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting

                                                AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.

                                                  Juno Reports Positive Phase I Study Data on Lymphoma Drug

                                                  Juno Therapeutics, Inc. (JUNO) announced encouraging preliminary clinical data from a phase I study (TRANSCEND) on its lead pipeline candidate, JCAR017, for the treatment of patients non-Hodgkin lymphoma (NHL).